scholarly journals Efflux excretion of bisdemethoxycurcumin‐O‐glucuronide in UGT1A1‐overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistance‐associated proteins 1 (MRP1) as the glucuronide transporters

BioFactors ◽  
2018 ◽  
Vol 44 (6) ◽  
pp. 558-569 ◽  
Author(s):  
Jing Yang ◽  
Beibei Zhang ◽  
Zifei Qin ◽  
Shishi Li ◽  
Jinjin Xu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multidrug Resistance ◽  
Hela Cells ◽  
Breast Cancer Resistance Protein ◽  
Cancer Resistance ◽  
Associated Proteins ◽  
Resistance Protein

scholarly journals Folium Sennae Increased the Bioavailability of Methotrexate through Modulation on MRP 2 and BCRP

2021 ◽  
Vol 14 (10) ◽  
pp. 1036
Author(s):  
Chung-Ping Yu ◽  
Yu-Hsuan Peng ◽  
Ching-Ya Huang ◽  
Yow-Wen Hsieh ◽  
Yu-Chi Hou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multidrug Resistance ◽  
Breast Cancer Resistance Protein ◽  
Systemic Exposure ◽  
Cancer Resistance ◽  
Parallel Design ◽  
Dosage Regimens ◽  
Combined Use ◽  
Associated Proteins ◽  
Resistance Protein

Folium Sennae (FS), a popular laxative (Senna), contains polyphenolic anthranoids, whose conjugation metabolites are probable modulators of multidrug resistance-associated proteins (MRPs) and breast cancer resistance protein (BCRP). We suspected that the combined use of FS might alter the pharmacokinetics of various medicines transported by MRPs or BCRP. This study investigated the effect of FS on the pharmacokinetics of methotrexate (MTX), an anticancer drug and a probe substrate of MRPs/BCRP. Rats were orally administered MTX alone and with two dosage regimens of FS in a parallel design. The results show that 5.0 g/kg of FS significantly increased the AUC0–2880, AUC720–2880 and MRT of MTX by 45%, 102% and 42%, and the seventh dose of 2.5 g/kg of FS significantly enhanced the AUC720–2880 and MRT by 78% and 42%, respectively. Mechanism studies indicated that the metabolites of FS (FSM) inhibited MRP 2 and BCRP. In conclusion, the combined use of FS increased the systemic exposure and MRT of MTX through inhibition on MRP 2 and BCRP.

Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs)

Xenobiotica ◽  
2015 ◽  
Vol 46 (5) ◽  
pp. 416-423 ◽  
Author(s):  
Jakub Hofman ◽  
Radim Kučera ◽  
Zuzana Neumanova ◽  
Jiri Klimes ◽  
Martina Ceckova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multidrug Resistance ◽  
Breast Cancer Resistance Protein ◽  
Cancer Resistance ◽  
P Glycoprotein ◽  
Associated Proteins ◽  
Resistance Protein ◽  
Placental Passage

scholarly journals Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines

1999 ◽  
Vol 91 (5) ◽  
pp. 429-433 ◽  
Author(s):  
D. D. Ross ◽  
W. Yang ◽  
L. V. Abruzzo ◽  
W. S. Dalton ◽  
E. Schneider ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multidrug Resistance ◽  
Cell Lines ◽  
Messenger Rna ◽  
Breast Cancer Resistance Protein ◽  
Rna Expression ◽  
Cancer Resistance ◽  
Resistance Protein

scholarly journals Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance

2004 ◽  
Vol 64 (12) ◽  
pp. 4346-4352 ◽  
Author(s):  
Yasuo Imai ◽  
Satomi Tsukahara ◽  
Sakiyo Asada ◽  
Yoshikazu Sugimoto
Keyword(s):  
Breast Cancer ◽  
Multidrug Resistance ◽  
Breast Cancer Resistance Protein ◽  
Cancer Resistance ◽  
Resistance Protein
Sign in / Sign up

Export Citation Format

Share Document